BioNTech SE (BNTX) Non-Current Deferred Tax Liability (2020 - 2025)

BioNTech SE has disclosed Non-Current Deferred Tax Liability across 6 years of filings, most recently posting $98.1 million for Q4 2025.

• Non-Current Deferred Tax Liability for Q4 2025 came in at $98.1 million, up 116.58% year-over-year; the trailing twelve-month figure through Dec 2025 was $98.1 million (up 116.58% YoY), and the FY2025 annual result was $95.2 million, up 110.21% from the prior year.
• Non-Current Deferred Tax Liability came in at $98.1 million for Q4 2025 at BioNTech SE, up from $28.3 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $107.1 million in Q2 2022 to a low of $4.9 million in Q2 2023.
• The 5-year median for Non-Current Deferred Tax Liability is $42.7 million (2023), against an average of $42.9 million.
• Across the five-year window, Non-Current Deferred Tax Liability jumped 31898.45% in 2021 and plunged 95.43% in 2023, its largest moves.
• BioNTech SE's Non-Current Deferred Tax Liability stood at $76.3 million in 2021, then slumped by 91.71% to $6.3 million in 2022, then jumped by 575.28% to $42.7 million in 2023, then climbed by 6.07% to $45.3 million in 2024, then surged by 116.58% to $98.1 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $98.1 million (Q4 2025), $28.3 million (Q3 2025), and $32.3 million (Q2 2025), per Business Quant data.